CN101817787A - The androgen receptor antagonist of anti-prostate cancer - Google Patents
The androgen receptor antagonist of anti-prostate cancer Download PDFInfo
- Publication number
- CN101817787A CN101817787A CN201010120494A CN201010120494A CN101817787A CN 101817787 A CN101817787 A CN 101817787A CN 201010120494 A CN201010120494 A CN 201010120494A CN 201010120494 A CN201010120494 A CN 201010120494A CN 101817787 A CN101817787 A CN 101817787A
- Authority
- CN
- China
- Prior art keywords
- compound
- methyl
- cyano group
- treatment
- prostate cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 52
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 52
- 229940123407 Androgen receptor antagonist Drugs 0.000 title abstract description 22
- 239000003936 androgen receptor antagonist Substances 0.000 title abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 100
- 102000001307 androgen receptors Human genes 0.000 claims abstract description 33
- 108010080146 androgen receptors Proteins 0.000 claims abstract description 33
- 206010000496 acne Diseases 0.000 claims abstract description 8
- 201000004384 Alopecia Diseases 0.000 claims abstract description 7
- 231100000360 alopecia Toxicity 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 229910052736 halogen Chemical group 0.000 claims description 14
- 150000002367 halogens Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims description 8
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- -1 CF 3 Chemical group 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 150000003527 tetrahydropyrans Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 239000002831 pharmacologic agent Substances 0.000 abstract description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract description 2
- 238000001819 mass spectrum Methods 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 40
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 26
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 24
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 23
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 23
- 125000003003 spiro group Chemical group 0.000 description 22
- 239000003814 drug Substances 0.000 description 15
- 229960000997 bicalutamide Drugs 0.000 description 14
- 229940088597 hormone Drugs 0.000 description 14
- 239000005556 hormone Substances 0.000 description 14
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 13
- NAGFMACWWJYORB-UHFFFAOYSA-N 2-fluoro-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1F NAGFMACWWJYORB-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000003163 gonadal steroid hormone Substances 0.000 description 13
- 230000002194 synthesizing effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- CCCIJQPRIXGQOE-XWSJACJDSA-N 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C=C2 CCCIJQPRIXGQOE-XWSJACJDSA-N 0.000 description 5
- 230000003042 antagnostic effect Effects 0.000 description 5
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000003810 ethyl acetate extraction Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 230000008484 agonism Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 206010068168 androgenetic alopecia Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960002074 flutamide Drugs 0.000 description 3
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000001548 androgenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 229940095102 methyl benzoate Drugs 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 230000035946 sexual desire Effects 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- NDZJSUCUYPZXPR-UHFFFAOYSA-N 1-nitro-2-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC=CC=C1C(F)(F)F NDZJSUCUYPZXPR-UHFFFAOYSA-N 0.000 description 1
- MMWFMFZFCKADEL-UHFFFAOYSA-N 2-fluoro-4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1F MMWFMFZFCKADEL-UHFFFAOYSA-N 0.000 description 1
- CWGRZEVFBBAKCD-UHFFFAOYSA-N 2-fluoro-n-methyl-4-nitrobenzamide Chemical compound CNC(=O)C1=CC=C([N+]([O-])=O)C=C1F CWGRZEVFBBAKCD-UHFFFAOYSA-N 0.000 description 1
- MWFMGBPGAXYFAR-UHFFFAOYSA-N 2-hydroxy-2-methylpropanenitrile Chemical compound CC(C)(O)C#N MWFMGBPGAXYFAR-UHFFFAOYSA-N 0.000 description 1
- UGWULZWUXSCWPX-UHFFFAOYSA-N 2-sulfanylideneimidazolidin-4-one Chemical compound O=C1CNC(=S)N1 UGWULZWUXSCWPX-UHFFFAOYSA-N 0.000 description 1
- DRNJIKRLQJRKMM-UHFFFAOYSA-N 4-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=C(C#N)C=C1 DRNJIKRLQJRKMM-UHFFFAOYSA-N 0.000 description 1
- XOKAXPQJUODMSH-UHFFFAOYSA-N 4-amino-2-fluoro-n-methylbenzamide Chemical compound CNC(=O)C1=CC=C(N)C=C1F XOKAXPQJUODMSH-UHFFFAOYSA-N 0.000 description 1
- RGHJWZADAWEIFE-UHFFFAOYSA-N 4-amino-2-methylbenzonitrile Chemical compound CC1=CC(N)=CC=C1C#N RGHJWZADAWEIFE-UHFFFAOYSA-N 0.000 description 1
- 229940124011 Androgen receptor agonist Drugs 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 230000010748 Photoabsorption Effects 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000516 activation analysis Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940125648 antineoplastic drug candidate Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000036782 biological activation Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011472 radical prostatectomy Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The androgen receptor antagonist of the anti-prostate cancer of the present invention relates to a class thiocarbamoyl imidazole diketone, and two nitrogen-atoms all has substituted radical; And relate to the such compound of use as pharmacological agent androgen receptor relevant disease or imbalance, for example prostate cancer, alopecia or comedo.
Description
Technical field
The present invention relates to a class thiocarbamoyl imidazole diketone, two nitrogen-atoms all has substituted radical; And relate to the such compound of use as pharmacological agent androgen receptor (Androgen Receptor, ' AR ') relevant disease or imbalance, for example prostate cancer, alopecia or comedo.
Background technology
(androgen receptor is a trans transcription regulatory protein that the ligand dependent of 110,000 Dalton molecular weights is arranged AR) to androgen receptor, belongs to steroid hormone nuclear receptor superfamily member, mainly is present in the nuclear of target cell.Androgen receptor is all to play the part of important effect in the pathogeny of prostate cancer or its deterioration process.It and special steroid hormone aglucon such as testis cave or more effective pair of hydrogen testis cave (DTH) are in the combination of ligand binding domain, cause conformational change, thereby (hsp) dissociates with heat shock protein(HSP), cause that the androgen receptor activation makes it to increase with DNA avidity, the activatory androgen receptor combines with specific dna sequence dna-androgen response element (ARE) in dimeric forms and the target cell nuclear, and in nucleus, move and other transcription factor interaction, thereby the adjusting target gene expression, the propagation of pair cell, existence and differentiation produce corresponding biological effect.Androgen receptor is played an important role in the relevant disease of many male hormones, for example prostate cancer, benign prostate enlargement, comedo and male pattern baldness etc.
Having the optionally main effect of androgen receptor antagonist (AR antagonist) is directly to stop testis cave or Standone (DHT) to combine with androgen receptor, the effect of blocking-up male sex hormone pair cell, make cell produce " hunger " phenomenon, thereby make apoptosis.It can be used for: a) male contraception; B) for example sexual desire is crossed strong and the sexual desire imbalance in the imbalance that a series of male hormones of treatment are relevant; C) treatment comprises illnesss such as benign prostate enlargement, comedo, bald and hair hyperplasia; D) prevent to reduce for example heating after the castration of relevant symptom with male hormone; E) be specifically designed to and prevent from or suppress the muscle of sex change women in commentaries on classics property therapeutic process to increase; F) anticancer change growth medicine and cooperation hormonotherapy treatment prostate cancer; G) prevention, prevention or elimination prostate cancer.
Prostate cancer is in sickness rate first mortality ratio the second in male sex's malignant tumour, only just there are 186320 new patients with prostate cancer in the U.S. in 2008 by diagnosis and therefore 26660 patients die.Though the sickness rate of China is far below the west, along with improving constantly of standard of living and diagnostic techniques, the sickness rate of prostate cancer is continuous ascendant trend.Prostate cancer is a kind of progress malignant tumour more rapidly, if can not get early stage diagnosis and treatment, from finding symptom, average survival time has only 3～5 years.On the concrete grammar of prostate cancer therapy, operation castration { radical prostatectomy (TLRRP), transurethral prostatectomy (TURP) and bilateral orchidectomy } and medicine castration { r-hLH (LHRH) antagonist and gonadotropin releasing hormone (GnRH) antagonist } be the first-selected means for the treatment of at the initial stage, simultaneously in conjunction with methods of treatment such as internal secretion, immunity, differentiation, gene and radiation.The male sex hormone major part is from testis, and small part is from suprarenal gland; The surgery castration can only be removed the male sex hormone from testis, and suprarenal gland still can be secreted a large amount of steroidals and produce some male sex hormones and enter prostata tissue and be released in the blood.Prostate cancer has higher susceptibility to male sex hormone.In order to reach the purpose for the treatment of prostate cancer, must suppress androgenic synthetic, the interaction of prevention and endonuclear androgen receptor (AR), thus block androgenic physiological action.Common male sex hormone blocking treatment (ADT) mainly carries out round this gonad axis of hypothalamus-hypophysis-testis that male sex hormone produces, and pharmacological agent is divided into: 1) endocrine axis blocking treatment; 2) directly suppressing male sex hormone synthesizes and 3) androgen receptor antagonists.Androgen receptor antagonists (AR Antagonist) and antiandrogen drug combination, be prostate cancer (the Castration Resistant Prostate Cancer that present stage control castration lost efficacy, be called for short CRPC) the most effective drug treatment, it begins all very effective to most advanced prostate cancer, but prostate cancer cell finally can adapt to the environment of lower concentration male hormone and treatment is produced resistance, and result's prostate cancer in three to five years almost all can recur and cause death in these all patients.
Androgen receptor antagonist (AR antagonist) the medicine for example initial design of Ni Lumi amine (Niluamide), flutamide (Flutamide) and bicalutamide (Bicalutamide, trade name Casodex) is to be used for avoiding the side effect of hormonotherapy and the resistance of eliminating the prostate cancer patient.Although these androgen receptor antagonists are respond well to the advanced prostate cancer patient who receives treatment first when being used with hormonotherapy, still be that the prostate cancer curative effect of their antagonism property of medicine of combination therapy is very limited no matter as using separately.Recent study shows, bicalutamide as the specificity of androgen receptor (AR) antagonist a little less than, and certain activated receptor effect (agonism) (flutamide also has been found similar problem) is arranged.Current research shows that reactivating of androgen receptor signalling channel may be the basic reason that hormonotherapy is developed immunity to drugs, it has limited for example curative effect of bicalutamide treatment prostate cancer of androgen receptor antagonist medicine that existing market generally uses, particularly for resistivity prostate cancer in late period.In addition, the curative effect of these androgen receptor antagonist medicines also generally is subject to their pronounced side effects, and is for example toxic to liver or central nervous system.So the prostate cancer clinical treatment presses for the high reactivity hypotoxicity and does not have the androgen receptor antagonist of new generation of remaining activating property (agonism).Among the present invention, on chemical structure, replace classical androgen receptor as 4-trifluoromethylbenzonitrile and trifluoromethyl nitrobenzene in conjunction with element, might improve specificity and reduce or eliminate the androgen receptor antagonist Side effects of pharmaceutical drugs used the clinically now toxicity of liver or central nervous system (for example to), these compounds can combine with androgen receptor, the inhibition acceptor moves in nucleus and reduces its transcriptional activity, is expected to become the androgen receptor antagonism drug candidate of treatment advanced prostate cancer.
Summary of the invention
The present invention includes compound, use this compounds (salt that comprises them) and pharmaceutical composition thereof method as androgen receptor antagonist (AR antagonist) with following chemical structure of general formula (I).
Compound with chemical structure of general formula (I):
R wherein
1Be selected from
Wherein R ' is methyl, ethyl or CF
3Y is methyl, CF
3, cyano group or halogen;
Wherein W is Sauerstoffatom, sulphur atom or two hydrogen atoms;
R wherein
3And R
4Be that independently methyl or they form a C together separately
3-5Cycloalkyl;
R wherein
2Be selected from such as the aromatic base of phenyl and substituent thereof, such as the assorted aromatic base of pyridine and substituent, alkyl and substituent thereof, such as the saturated heterocyclic and the substituent thereof of 3-or 4-pyridine or tetrahydropyrans or 3-tetramethyleneimine or tetrahydrofuran (THF).
Compound with chemical structure of general formula (I), R
1Be selected from
Wherein R ' is methyl, ethyl or CF
3Y ' is methyl, CF
3
R wherein
3And R
4Form C together
3-5Cycloalkyl.
Compound with chemical structure of general formula (I), R
1Be selected from
Y " be cyano group or halogen.
Compound with chemical structure of general formula (I), wherein R
2Be aromatic base and have following substituted radical :-C (O) NHR " ,-C (O) OR " ,-SO
2Me ,-SO
2NHR ", cyano group, hydroxyl, alkoxyl group ,-C (S) NHR " ,-C (O) OR ", halogen or 5 to 6 yuan of assorted aromatic bases; R wherein " be selected from hydrogen atom, C
1-6Alkyl, C
1-6Cycloalkyl or C
1-6Thiazolinyl.
Compound with chemical structure of general formula (I), wherein R
2Be assorted aromatic base and have following substituted radical :-C (O) NHR " ,-C (O) OR " ,-SO
2Me ,-SO
2NHR ", cyano group, hydroxyl, alkoxyl group ,-C (S) NHR " ,-C (O) OR ", halogen or 5 to 6 yuan of assorted aromatic bases; R wherein " be selected from hydrogen atom, C
1-6Alkyl, C
1-6Cycloalkyl or C
1-6Thiazolinyl.
Above compound has following chemical structure of general formula (II)
R wherein
1' be selected from
Wherein R ' is methyl, ethyl or CF
3Y ' is methyl, CF
3
R wherein
3' and R
4' form C together
3-5Cycloalkyl;
Wherein B is selected from cyano group, methyl, CF
3Or halogen;
Wherein A is selected from-C (O) NHCH
3,-C (O) NH
2,-C (O) OCH
3,-C (O)) CH
2CH
3, cyano group, hydroxyl, alkoxyl group ,-SO
2Me, methyl ,-SO
2NHMe or-SO
2NH
2
Wherein W is a Sauerstoffatom.
Compound also can have following chemical structure of general formula (III)
R wherein
1" be selected from
Y " be cyano group or halogen;
Wherein B is selected from cyano group, methyl, CF
3Or halogen;
Wherein A is selected from-C (O) NHCH
3,-C (O) NH
2,-C (O) OCH
3,-C (O)) CH
2CH
3, cyano group, hydroxyl, alkoxyl group ,-SO
2Me, methyl ,-SO
2NHMe or-SO
2NH
2
Wherein W is a Sauerstoffatom.
Compound also can have following chemical structural formula
The present invention includes the synthetic top method of describing compound.
Use with the compound or pharmaceutically acceptable salt thereof among the present invention or prodrug pharmaceutical composition as activeconstituents, the method of the active associated conditions of treatment and androgen receptor comprises treatment prostate cancer (comprising responsive and insensitive patient to hormonotherapy), alopecia, dark sore and comedo etc.
Description of drawings
Accompanying drawing 1 is the medicine kinetics behind oral example 6 compounds of mouse, has shown blood substance concentration over time.
Embodiment
Synthesizing of compound
The compound that the present invention has chemical structure of general formula (I) can prepare with synthetic route that describes below and condition.
General synthetic route 1
Shown in the as above general synthetic route 1, isothiocyanic acid acyl ester 3 (isothiocyanate) can obtain by aniline 1 and thiophosgene (thiophosgene) reaction.The preparation of intermediate 6 is by under the situation that has TMSCN or sodium cyanide to exist aniline 4 (or alkyl ammonia) and ketone 5 being dewatered.This step condensation reaction also can be by reacting with aniline 4 (or alkyl ammonia) and corresponding ketone cyanalcohol (ketonecyanohydrin) under the situation that has sal epsom to exist.Final product thio-hydantoin (chemical structure of general formula I) can obtain from the reaction of intermediate 3 and intermediate 6.Aniline or alkyl ammonia 1 can be bought and obtain or with known references method preparation (for example reduce oil of mirbane).
Synthesizing of example 1
Synthesizing of 4-isothiocyanic acid-3-trifluoromethoxy-benzonitrile (intermediate 3a)
Thiophosgene (4.21g, slowly add in aqeous suspension 36.6mmol) (30mL) 4-amino-2-methyl-benzonitrile 1a (5g, 34.9mmol).The mixture that obtains after stirring one hour, room temperature (25oC) is used ethyl acetate extraction three times (3 * 25mL).Merge organic layer, and washing (1 * 50mL), dry (MgSO4), vacuum is drained and is obtained light brown solid 3a (intermediate 7,6.5g, 100% yield), is directly used in next step reaction.
Synthesizing of 2-fluoro-N-methyl-4-nitro-benzamide (intermediate 8)
(15g, (20g, (DMF, 20mL) solution is at-5 ℃ for dimethyl formamide 110mmol) 130mmol) to splash into 2-fluoro-4-nitro-phenylformic acid 7 slowly with sulfur oxychloride.Stir dropwise add after 1 hour methylamine (400mL, 800mmol).Slowly be warmed up to room temperature.To going into the 125ml frozen water, ethyl acetate extraction, the salt water washing, dried over mgso concentrates, and crystallization obtains yellow solid compound 8 (20g, 90%).
1H?NMR(acetone-d
6，500MHz)δ(ppm)7.66(1H，dd，J＝8.5，8.5Hz)，6.41(1H，dd，J＝8.6，2.1Hz)，6.32(1H，dd，J＝13.6，2.0Hz)，3.05(3H，d，J＝4.4Hz)。Mass spectrum: 163 (M+H
+).
Synthesizing of 4-amino-2-fluoro-N-methyl-benzamide (intermediate 9)
(3g 15.1mmol) is dissolved in the solution of ethyl acetate and acetate (12mL+12mL) with compound 8.Add the 8g iron powder and reflux, LCMS detects, and finishes cool to room temperature until reaction.Cross filter solid, the ethyl acetate washing solid with 50mL merges organic phase, the salt water washing, and dried over mgso concentrates, and obtains yellow solid compound 9 (2.5g, 97%).
1H?NMR(acetone-d
6，500MHz)：δ(ppm)7.69(1H，dd，J＝8.7，8.8Hz)，7.15(1H，s)，6.51(1H，dd，J＝8.6，2.1Hz)，6.38(1H，dd，J＝14.7，2.1Hz)，5.70(1H，br?s)，2.88(3H，d，J＝4.3Hz)。Mass spectrum: 169 (M+H
+).
Synthesizing of 4-(1-cyano group-ring fourth amino)-2-fluoro-N-methyl-benzamide (intermediate 10)
With TMS-CN (29.7g, 300mmol), cyclobutanone (14g, 200mmol), compound 9 (16.8g 100mmol) is dissolved in the 200mL acetate, heat 80 ℃ 24 hours.Reaction finishes the back and adds 200mL water, uses ethyl acetate extraction, the salt water washing, and dried over mgso concentrates, and with normal hexane and ether (20mL-20mL) washing, filters and obtains product 10 (20g, 84%).
1H?NMR(CDCl
3，300MHz)：δ(ppm)7.92(1H，dd，J＝8.4，8.4Hz)，6.76(1H，q，J＝4.3Hz)，6.48(1H，dd，J＝8.3，1.9Hz)，6.29(1H，dd，J＝14.3，1.9Hz)，4.72(1H，br?s)，2.97(3H，d，J＝4.4Hz)，2.85-2.75(2H，m)，2.4-2.35(2H，m)，2.3-2.15(1H，m)，1.95-1.85(1H，m)。Mass spectrum: 246 (M-H).
4-[7-(4-cyano group-2-trifluoromethoxy-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-5-
Base]-2-fluoro-N-methyl-benzamide (example 1) synthetic
Example 1
With compound 10 (392mg, 1.58mmol) and 3a (494mg 2.02mmol) is dissolved in DMF (5mL), 110 ℃ of microwave heatings, 12h.Add methyl alcohol (10mL) and HCl (2N, 5mL) reflux 1h.Ethyl acetate extraction, the salt water washing, dried over mgso concentrates.PE: EA/1: 1 crosses post obtains examples of compounds 1 (250mg, 25%).
1H?NMR(CDCl
3，500MHz)：δ(ppm)8.30(1H，dd，J＝8.6，3.5Hz)，7.70(2H，dd，J＝8.0，1.5Hz)，7.63(1H，d，J＝8.5Hz)，7.26(1H，m)，7.15(1H，dd，J＝11.5，1.5Hz)，6.60(1H，br?s)，3.00(3H，d，J＝5Hz)，2.65(2H，m)，2.52(2H，m)，2.27(1H，m)，1.70(1H，m)。Mass spectrum: 493 (M+H).
4-[7-(4-cyano group-2-fluoro-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-5-yl]-2-
Synthesizing of fluoro-N-methyl-benzamide (example 2)
Example 2
Example 2 is to obtain with the reaction by intermediate 10 and 7b of the method for similar synthetic example 1 that (yield: 23%), 7b is that the method with similar synthetic 7a obtains from corresponding aniline reaction.
1H NMR (CDCl
3, 500MHz): δ (ppm) 8.30 (1H, dd, J=8.6,3.5Hz), 7.57 (3H, m), 7.26 (1H, m), 7.15 (1H, dd, J=12.0,2.0Hz), 6.71 (1H, br s), 3.00 (3H, d, J=5Hz), 2.65 (2H, m), 2.52 (2H, m), 2.27 (1H, m), 1.70 (1H, br m). mass spectrum: 427 (M+H
+).
4-[7-(4-cyano group-2-methyl-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-5-yl]-
Synthesizing of 2-fluoro-N-methyl-benzamide (example 3)
Example 3
Example 3 is to obtain with the reaction by intermediate 10 and 7c of the method for similar synthetic example 1 that (yield: 21%), 7c is that the method with similar synthetic 7a obtains from corresponding aniline reaction.
1H NMR (CDCl
3, 500MHz): δ (ppm) 8.30 (1H, dd, J=8.6,3.5Hz), 7.67 (2H, m), 7.38 (1H, d, J=8.0Hz), 7.26 (1H, m), 7.20 (1H, dd, J=11.5,2.0Hz), 6.71 (1H, br s), 3.00 (3H, d, J=5Hz), 2.65 (2H, m), 2.52 (2H, m),, 2.15 (3H, s), 2.15 (1H, m), 1.68 (1H, br m). mass spectrum: 423 (M+H
+).
4-[7-(4-cyano group-2-trifluoromethyl-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-5-
Base]-2-fluoro-N-methyl-benzamide (example 4) synthetic
Example 4
Example 4 is to obtain with the reaction by intermediate 10 and 7d of the method for similar synthetic example 1 that (yield: 22%), 7d is that the method with similar synthetic 7a obtains from corresponding aniline reaction.
1H?NMR(CDCl
3，500MHz)：δ(ppm)8.30(1H，dd，J＝8.6，3.5Hz)，8.12(1H，d，J＝1.5Hz)，8.01(1H，dd，J＝8.5，2.0Hz)，7.58(1H，d，J＝8.0Hz)，7.26(1H，m.br)，7.15(1H，dd，J＝11.5，2.0Hz)，6.71(1H，br?s)，3.00(3H，d，J＝5Hz)，2.70(2H，m)，2.52(2H，m)，2.15(1H，m)，1.68(1H，br?m)。Mass spectrum: 477 (M+H
+).
4-[7-(4-cyano group-2-chloro-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-5-yl]-2-
Synthesizing of fluoro-N-methyl-benzamide (example 5)
Example 5
Example 5 is to obtain with the reaction by intermediate 10 and 7e of the method for similar synthetic example 1 that (yield: 23%), 7e is that the method with similar synthetic 7a obtains from corresponding aniline reaction.
1H?NMR(CDCl
3，500MHz)：δ(ppm)8.39(1H，t，J＝9.0Hz)，7.89(1H，s)，7.72(1H，dd，m)，7.54(1H，d，J＝8.0Hz)，7.26(1H，m.br)，7.20(1H，d，J＝11Hz)，6.71(1H，br?s)，3.00(3H，d，J＝5Hz)，2.70(2H，m)，2.52(2H，m)，2.26(1H，m)，1.69(1H，m，br)。Mass spectrum: 443 (M+H
+).
4-[7-(4-cyano group-3-methoxyl group-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-5-
Base]-2-fluoro-N-methyl-benzamide (example 6) synthetic
Example 6
Example 6 is to obtain with the reaction by intermediate 10 and 7f of the method for similar synthetic example 1 that (yield: 20%), 7f is that the method with similar synthetic 7a obtains from corresponding aniline reaction.
1H?NMR(CDCl
3，500MHz)：δ(ppm)8.39(1H，t，J＝9.0Hz)，7.62(1H，d，J＝8.0Hz)，7.26(1H，m.br)，7.18(1H，d，J＝10.0Hz)，7.10(2H，m)，6.71(1H，br?s)，3.97(3H，s)，3.00(3H，d，J＝5Hz)，2.70(2H，m)，2.52(2H，m)，2.26(1H，m)，1.69(1H，br?m).。Mass spectrum: 439 (M+H
+).
4-[7-(3,4-dicyano-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-5-yl]-2-
Synthesizing of fluoro-N-methyl-benzamide (example 7)
Example 7
Example 7 is to obtain with the reaction by intermediate 10 and 7g of the method for similar synthetic example 1 that (yield: 20%), 7g is that the method (temperature of reaction is 0 ℃) with similar synthetic 7a obtains from corresponding aniline reaction.
1HNMR(CDCl
3，500MHz)：8.39(1H，t，J＝9.0Hz)，8.00(1H，d，J＝2.0Hz)，7.90(2H，m.br)，7.26(1H，m.br)，7.18(1H，dd，J＝11.5，2.0Hz)，6.71(1H，brs)，3.00(3H，d，J＝5Hz)，2.70(2H，m)，2.52(2H，m)，2.26(1H，m)，1.62(1H，m，br)。Mass spectrum: 434 (M+H
+).
Following example is to be similar to the method for synthetic example 1-7, to adopt synthetic the obtaining of mode of parallel chemistry.
Example 8:4-[7-(4-cyano group-3-trifluoromethoxy-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-5-yl]-2-fluoro-N-methyl-benzamide.Mass spectrum (ESP): 493 (M+H
+).
Following example is the method for synthesizing example 1 to be similar to, and adopts synthetic the obtaining of mode of parallel chemistry, and wherein aniline intermediate 9 is replaced by other corresponding aniline.
Example 9:4-[5-(3-fluoro-4-methyl-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-7-yl]-the adjacent dintrile of benzene.Mass spectrum (ESP): 391 (M+H
+).
The adjacent dintrile of example 10:4-(8-oxo-6-sulfo--5-p-methylphenyl-5,7-diaza spiro [3,4] octane-7-yl)-benzene.Mass spectrum (ESP): 373 (M+H
+).
Example 11:4-[5-(3-fluoro-4-methyl-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-7-yl]-2-methoxyl group-benzene nitrile.Mass spectrum (ESP): 396 (M+H
+).
Example 12:2-methoxyl group-4-(8-oxo-6-sulfo--5-p-methylphenyl-5,7-diaza spiro [3,4] octane-7-yl]-the benzene nitrile.Mass spectrum (ESP): 378 (M+H
+).
Example 13:2-methoxyl group-4-[5-(6-methyl-pyridin-3-yl)-8-oxo-6 sulfo--5,7-diaza spiro [3,4] octane-7-yl]-the benzene nitrile.Mass spectrum (ESP): 379 (M+H
+).
Example 14:2-methoxyl group-4-[5-(6-methoxyl group-pyridin-3-yl)-8-oxo-6 sulfo--5,7-diaza spiro [3,4] octane-7-yl]-the benzene nitrile.Mass spectrum (ESP): 395 (M+H
+).
Example 15:4-[5-(4-fluoro-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-7-yl]-2-methoxyl group-benzene nitrile.Mass spectrum (ESP): 382 (M+H
+).
Example 16:2-methoxyl group-4-[8-oxo-6-sulfo--5-(4-trifluoromethyl-phenyl)-5,7-diaza spiro [3,4] octane-7-yl]-the benzene nitrile.Mass spectrum (ESP): 432 (M+H
+).
Example 17:4-[5-(4-chloro-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-7-yl]-2-methoxyl group-benzene nitrile.Mass spectrum (ESP): 399 (M+H
+).
Example 18:4-[5-(3,4-two fluoro-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-7-yl]-2-methoxyl group-benzene nitrile.Mass spectrum (ESP): 400 (M+H
+).
Example 19:4-[5-(3-fluoro-4-cyano group-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-7-yl]-2-methoxyl group-benzene nitrile.Mass spectrum (ESP): 407 (M+H
+).
Example 20:2-methoxyl group-4-(8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-7-yl]-the benzene nitrile.Mass spectrum (ESP): 364 (M+H
+).
Example 21:4-[7-(4-cyano group-3-methoxyl group-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-5-yl]-methyl benzoate.Mass spectrum (ESP): 422 (M+H
+).
Example 22:4-[7-(4-cyano group-3-methoxyl group-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-5-yl]-ethyl benzoate.Mass spectrum (ESP): 436 (M+H
+).
Example 23:4-[5-(4-methylol-phenyl)-8-oxo-6-sulfo--5,7-diaza spiro [3,4] octane-7-yl]-2-methoxyl group-benzene nitrile.Mass spectrum (ESP): 394 (M+H
+).
Following example is the method for synthesizing example 1 to be similar to, and adopts synthetic the obtaining of mode of parallel chemistry, and intermediate cyclobutanone is wherein replaced by acetone or acetone cyanohydrin.
Example 24:4-[3-(3,4-dicyano-phenyl)-5,5-dimethyl-4-oxo-2-sulfo--imidazolidine-1-yl]-2-fluoro-N-methyl-benzamide.Mass spectrum (ESP): 422 (M+H
+).
Example 25:4-[3-(3-fluoro-4-methyl-phenyl)-4,4-dimethyl-5-oxo-2-sulfo--imidazolidine-1-yl]-the adjacent dintrile of benzene.Mass spectrum (ESP): 379 (M+H
+).
Example 26:4-(4,4-dimethyl-5-oxo-2-sulfo--3-p-methylphenyl-imidazolidine-1-yl]-the adjacent dintrile of benzene.Mass spectrum (ESP): 361 (M+H
+).
Example 27:4-[4,4-dimethyl-3-(6-methyl-pyridin-3-yl)-5-oxo-2-sulfo--imidazolidine-1-yl]-the adjacent dintrile of benzene.Mass spectrum (ESP): 362 (M+H
+).
Example 28:4-[3-(6-methoxyl group-pyridin-3-yl)-4,4-dimethyl-5-oxo-2-sulfo--imidazolidine-1-yl]-the adjacent dintrile of benzene.Mass spectrum (ESP): 378 (M+H
+).
Example 29:4-[3-(4-fluoro-phenyl)-4,4-dimethyl-5-oxo-2-sulfo--imidazolidine-1-yl]-the adjacent dintrile of benzene.Mass spectrum (ESP): 365 (M+H
+).
Example 30:4-[4,4-dimethyl-5-oxo-2-sulfo--3-(4-trifluoromethyl-phenyl)-imidazolidine-1-yl]-the adjacent dintrile of benzene.Mass spectrum (ESP): 415 (M+H
+).
Example 31:4-[3-(4-chloro-phenyl)-4,4-dimethyl-5-oxo-2-sulfo--imidazolidine-1-yl]-the adjacent dintrile of benzene.Mass spectrum (ESP): 382 (M+H
+).
Example 32:4-[3-(3,4-two fluoro-phenyl)-4,4-dimethyl-5-oxo-2-sulfo--imidazolidine-1-yl]-the adjacent dintrile of benzene.Mass spectrum (ESP): 383 (M+H
+).
Example 33:4-[3-(4-cyano group-3-fluoro-phenyl)-4,4-dimethyl-5-oxo-2-sulfo--imidazolidine-1-yl]-the adjacent dintrile of benzene.Mass spectrum (ESP): 390 (M+H
+).
The adjacent dintrile of example 34:4-(4,4-dimethyl-5-oxo-3-phenyl-2-sulfo--imidazolidine-1-yl)-benzene.Mass spectrum (ESP): 347 (M+H
+).
Example 35:4-[3-(3,4-dicyano-phenyl)-5,5-dimethyl-4-oxo-2-sulfo--imidazolidine-1-yl]-methyl benzoate.Mass spectrum (ESP): 405 (M+H
+).
Example 36:4-[3-(3,4-dicyano-phenyl)-5,5-dimethyl-4-oxo-2-sulfo--imidazolidine-1-yl]-ethyl benzoate.Mass spectrum (ESP): 419 (M+H
+).
Example 37:4-[3-(4-methylol-phenyl)-4,4-dimethyl-5-oxo-2-sulfo--imidazolidine-1-yl]-the adjacent dintrile of benzene.Mass spectrum (ESP): 377 (M+H
+).
The external biological activation analysis
Compound involved in the present invention can become androgen receptor antagonists of new generation.Compare with the androgen receptor antagonists bicalutamide that present prostate tumor drug market is the most frequently used, the compound of our first-selection is antagonistic activity and the androgen receptor antagonists minimum or that be difficult to observed agonist activity with more effective androgen receptor.Discussed in the background of invention part as us, the androgen receptor antagonists of highly selective can effectively be used for the treatment of the androgen receptor diseases associated, particularly for the prostate cancer intractable of hormonotherapy sensitivity with hormonotherapy, and comedo and male pattern baldness or the like.When actual clinical was used, compound of the present invention can be to be used in combination separately or with one or more other medicines.
The compounds of this invention to the detection of androgen receptor antagonism (antagonism) and exciting (agonism) effect can by at the prostate cancer cell of hormone-sensitive (such as LNCaP, LAPC4) and the intractable prostate cancer cell of hormone (such as LNCaP-AR, LAPC4-AR, LNCaP C4-2,22RV1, VCaP, LNCaP-AI and LNCaP-abl) confirmed.The cell that we at first select for use, the one, LNCaP, the prostatic cell model of hormonotherapy sensitivity commonly used; The 2nd, 22RV1, the prostatic cell model of hormonotherapy refractory commonly used.They all express androgen receptor, and male sex hormone can be induced its prostate specific antigen (Prostate-SpecificAntigen, expression PSA), and can promote the growth of these cells.Prostate specific antigen is an important physical signs of prostate cancer, be subjected to the regulation and control of androgen receptor, can be used for our compound of being invented of comparison to the antagonistic ability of androgen receptor function so detect the level of prostate specific antigen (PSA) on corresponding prostate cancer cell model, and the growth-inhibiting of cell experiment simultaneously (adopting the MTT method) also can be used for estimating the inhibition ability of the carcinoma of prostate cell growth of these compounds.Further the oral pharmacokinetics of the test compound that we invented on rodents such as mouse and rat preferably to have moving character of medicine and stable compound in the good body, makes it to become the prostate cancer drug candidate with clinical prospect.The effective androgen receptor antagonists of these highly selectivies also can carry out the comparison and the assessment of drug effect in the body at the animal model of prostate cancer, alternative prostate gland corpus carcinosus inner model comprises LNCaP, LAPC4, LAPC9, CWR22, LNCaP-AR, LNCaP C4-2, VCaP, 22RV1, LNCaP-abl and LNCaP-AI are to take into account the prostate cancer clinical practice case intractable with hormone of reaction hormone-sensitive.
Prostate specific antigen (PSA) inhibition test
In order to detect compound that we invent antagonistic activity to androgen receptor, we measure the inhibition activity of these compounds to prostate specific antigen (PSA) on multiple prostate cancer cell, effectively induce the expression of PSA in cell to increase the susceptibility that suppresses experiment with artificial synthetic male sex hormone R1881 (Methyltrienolone, androgen receptor activator).Prostate cancer LNCaP and 22RV1 cell are androgen-dependent cells, all can buy from U.S. culture presevation storehouse (ATCC).These two kinds of cells can and contain 10% foetal calf serum (FBS) at the RPMI RPMI-1640, the penicillin of 100 units per ml, incubation growth in the amphotericin B of the Streptomycin sulphate of 100 mcg/ml and 0.25 mcg/ml, cell need remain on CO2gas incubator to guarantee the growth conditions of 37 ℃ of temperature and 5% carbonic acid gas.Go down to posterity LNCaP cell between 20 to 35 times and the 22RV1 cell that goes down to posterity between 30 to 50 times can be used for this experiment.LNCaP is a kind of cell strain of hormone-sensitive, and the 22RV1 intractable prostate cancer cell strain that is a kind of hormone.In order to detect prostate specific antigen (PSA), at first human prostate cancer LNCaP or 22RV1 cell transfer are cultured to and contain 10% RPMI RPMI-1640 through the foetal calf serum (Charcoal-stripped FBS) of charcoal treatment, cultivate after three days, be allocated in standard 96 porocyte culture plates with the concentration of every Kong Wuqian cell.Next day, in the nutrient solution of every hole, add ultimate density and be the male sex hormone R1881 of synthetic of 50 pmols (pM) concentration and the test compounds or the bicalutamide (compound as a comparison) of finite concentration gradient (ultimate density is the 0.001-10 micro-molar concentration).Continue to cultivate four days after adding compound, with euzymelinked immunosorbent assay (ELISA) (ELISA method) be determined at the supernatant nutrient solution prostate specific antigen (PSA) concentration.The level of enzyme linked immunological (ELISA) the test prostate specific antigen in can the Sensitive Detection cell culture fluid.Concrete experimentation is that adding nutrient solution and standard substance (every hole is 200 microlitres) on antibody-coated 96 orifice plates place the dropping point deck vibrator of maintenance 500-600 rotating speed at room temperature to react two hours this plate, wash 96 orifice plates then five times; Then with damping fluid with one to two ten the HRP binding substances is diluted, be added into each 96 orifice plate again.This 96 hole elisa plate at room temperature shook continuously 30 minutes and washed five times as previous step, added the TMB (3,3 ' of 100 microlitres then, 5,5 '-tetramethyl benzidine, concentration 0.4 grams per liter), then the ELISA vibration is ten minutes, adds 100 microlitre stop buffers and comes stopped reaction.Use the photoabsorption microplate reader to measure ELISA 96 orifice plates at 450 nanometer light waves (650 nanometer light waves as a reference), calculate that according to the resulting typical curve of standard substance that enzyme linked immunological (ELISA) test kit provides each 96 reacting hole is secreted into the concentration of the prostate specific antigen of supernatant nutrient solution, calculate the compound tested and bicalutamide 50 percent inhibition concentration (IC at last the prostate specific antigen (PSA) of the prostate cancer cell 22RV1 of the prostate cancer cell LNCaP of hormonotherapy sensitivity and hormonotherapy refractory
50), its result is as shown in table 1.
Table 1: prostate specific antigen (PSA) test data
| Examples of compounds | ??LNCaP??IC 50(nM) | ??22RV1??IC 50(nM) |
| Bicalutamide | ??1450 | ??4720 |
| Examples of compounds 1 | ??580 | ??890 |
| Examples of compounds 2 | ??510 | ??630 |
| Examples of compounds 3 | ??610 | ??540 |
| Examples of compounds 4 | ??450 | ??1240 |
| Examples of |
??750 | ??1530 |
| Examples of compounds 6 | ??190 | ??210 |
| Examples of compounds 7 | ??320 | ??350 |
| Examples of compounds 8 | ??220 | ??250 |
| Examples of compounds 9 | ??250 | ??340 |
| Examples of |
??120 | ??180 |
| Examples of compounds 11 | ??80 | ??210 |
| Examples of compounds 12 | ??150 | ??260 |
| Examples of compounds 24 | ??190 | ??320 |
| Examples of |
??100 | ??190 |
| Examples of compounds | ??LNCaP??IC 50(nM) | ??22RV1??IC 50(nM) |
| Examples of compounds 26 | ??110 | ??290 |
clearly show as table 1, carry out substituent variation at these compounds and can cause compound to the change on the antagonistic activity of androgen receptor with consistent division center.Many compounds such as these instantiation compounds, compare with bicalutamide, no matter be at the hormone-sensitive (LNCaP) or the prostate cancer cell of hormone refractory (22RV1), to the generation of prostate specific antigen (PSA) restraining effect, particularly examples of compounds 6-12 and 24-26, its antagonistic activity to androgen receptor is greatly improved, being expected to becomes aspect the prostate cancer than bicalutamide novel cpd efficiently in treatment, and may for example comedo and male pattern baldness etc. develop into effective medicine in other disease relevant with androgen receptor.
The prostate cancer cell growth inhibition test
Prostate cancer LNCaP and 22RV1 cell can and contain 10% foetal calf serum (FBS) at the RPMI RPMI-1640, the penicillin of 100 units per ml, merisis in the amphotericin B of the Streptomycin sulphate of 100 mcg/ml and 0.25 mcg/ml, when cell reaches 80-90% and converges, the cultivation of going down to posterity.For the compound of testing us growth-inhibiting ability to prostate cancer cell, at first human prostate cancer LNCaP or 22RV1 cell transfer are cultured to and contain 10% RPMI1640 nutrient solution through the foetal calf serum (Charcoal-stripped FBS) of charcoal treatment, cultivate after three days, cell is added on the standard 96 porocyte culture plates in 100 microlitre volumes with every Kong Shiwan number, place the carbonic acid gas cell cultures brooder of 37 ℃ of temperature to spend the night.Carefully remove cell culture fluid, the nutrient solution that adds 80 microlitre preheatings then in every hole, with 10 microlitres the test compounds of finite concentration gradient (ultimate density from 20 to 0.1 micro-molar concentrations) or bicalutamide compound is as a comparison arranged, under 37 ℃ of temperature, kept 30 minutes, the last male sex hormone R1881 (ultimate density is 50 pmols (pM) concentration) that adds 10 microlitre synthetic in every hole then kept 96 hours under 37 ℃ of temperature.When cultivate finishing, add 10 microlitre MTT reaction solutions in every hole, continued under 37 ℃ of temperature culturing cell two to four hours, make being able to fully of reaction of in survivaling cell dyestuff and mitochondrial dehydrogenase, naked eyes can be seen the throw out of purple.Add the washing reagent of 100 microlitres then in every hole of 96 porocyte culture plates, lucifuge kept two hours under the room temperature, detected its absorption at 570nm with microplate reader at last.The inhibition per-cent that is expressed as test compounds of experimental result, the multiple of its increase are to carry out the stdn adjustment in the test number that does not have test compounds to contain the male sex hormone R1881 of synthetic as 100% radix.Calculate 50 percent in view of the above and suppress (IC
50) value, the result is as shown in table 2.
Table 2: cell MTT experimental data
| Examples of compounds | ??LNCaP??IC 50(μM) | ??22RV1??IC 50(μM) |
| Bicalutamide | ??5.7 | ??8.9 |
| Examples of compounds 1 | ??3.6 | ??3.9 |
| Examples of compounds 6 | ??0.9 | ??1.2 |
| Examples of compounds 7 | ??1.8 | ??3.0 |
| Examples of compounds | ??LNCaP??IC 50(μM) | ??22RV1??IC 50(μM) |
| Examples of |
??0.8 | ??2.9 |
| Examples of compounds 12 | ??1.5 | ??3.9 |
| Examples of compounds 24 | ??2.9 | ??3.0 |
| Examples of compounds 26 | ??2.9 | ??3.6 |
With just compare at clinical widely used bicalutamide, no matter the compound that we give an example at table 2 is to produce more efficiently restraining effect to hormone-sensitive prostate cancer cell LNCaP or to the growth of the cell 22RV1 of hormone refractory.These to cancer cells suppress active higher compound for example example 6,10 and 12 be worth us to its stability in vivo and in vitro, suppress prostate cancer in pharmacokinetics behavior and the body and grow into further research of row, to confirm to find to be better than the androgen receptor agonist drug of new generation of bicalutamide.
Oral pharmacokinetic studies
30 of healthy male Balb mouse, fasting is random packet after 12 hours, irritates stomach (50mg/kg) and gives examples of compounds 6.After administration 0.5,1,2.0,4.0,6.0 and 24.0 hours veins get 0.5 milliliter of blood, put centrifugal 10min in the centrifuge tube of heparinization, separate and get blood plasma for sample analysis, we adopt liquid chromatography tandem mass spectrum (LC-MS/MS) to be the drug level in the blood plasma after the administration of interior mark detection assay with Proprasylyte (Propranolol), calculate it pharmacokinetic parameters and absolute bioavailability.The result irritates stomach examples of compounds 6 back Plasma Concentrations and keeps the long residence time (seeing accompanying drawing one), and its main pharmacokinetic parameters is as follows: Cmax is respectively 20.3 μ g/mL; T
MaxBe 4hr; T
1/2Be 41hr; AUC
0-24hBe 367 μ g*hr/mL; AUC
0-∞Be 1154 μ g*hr/mL.AUC according to intravenously administrable
0-∞Calculate, the absolute bioavailability of irritating the stomach preparation is 41%.The preliminary pharmacokinetic of mouse oral administration shows that examples of compounds 6 absorbs comparatively fast in the mouse body, the elimination transformation period is longer, and bioavailability is higher, shows that it can become the oral anticancer drug candidate of ideal.
The metabolic stability of compound
In order further to determine the metabolic stability of compound, we adopt human liver's microsome and a plurality of compound hatching reaction of the present invention, use liquid chromatography tandem mass spectrum (LC-MS/MS) method to detect remaining compound substance then.Compound sample is dissolved in dimethyl sulfoxide (DMSO) (DMSO), and further with reaction buffer dilution, with guarantee dimethyl sulfoxide (DMSO) content in the end reaction mixed solution less than 0.1%.Compound sample and human liver's microsome are spent hybrid reactions 0 to 60 minute 37, and the ice acetonitrile of mark Terfenadine is in different time point (0,5,10,20,30,45,60 minutes) termination reaction in containing with adding.Sample mixture is centrifugal, and (4000rpm 10min) gets clear liquid, and the supernatant liquor of different time points is analyzed with liquid chromatography tandem mass spectrum (LC-MS/MS) method.Determining of metabolic stability by comparing with 0 minute compound concentration at the remaining substance compound of different time points.The result shows that examples of compounds 6 is the most stable, transformation period (T
1/2) greater than 60 minutes, almost not degraded in external human body liver microsomes, and examples of compounds 10 and 12 is in people's hepatomicrosome less stable, transformation period (T
1/2) all be about 11 minutes.
Claims (16)
1. the compound that has following chemical structure of general formula (I):
Wherein:
R
1Be selected from
Wherein R ' is methyl, ethyl or CF
3Y is methyl, CF
3, cyano group or halogen;
Wherein W is Sauerstoffatom, sulphur atom or two hydrogen atoms;
R wherein
3And R
4Be that independently methyl or they form a C together separately
3-5Cycloalkyl;
R wherein
2Be selected from such as the aromatic base of phenyl and substituent thereof, such as the assorted aromatic base of pyridine and substituent, alkyl and substituent thereof, such as the saturated heterocyclic and the substituent thereof of 3-or 4-pyridine or tetrahydropyrans or 3-tetramethyleneimine or tetrahydrofuran (THF).
2. the compound of claim 1, wherein R
1Be selected from
Wherein R ' is methyl, ethyl or CF
3Y ' is methyl, CF
3
R wherein
3And R
4Form C together
3-5Cycloalkyl.
3. the compound of claim 1, wherein R
1Be selected from
Y " be cyano group or halogen.
4. claim 2 and 3 compound, wherein R
2Be aromatic base and have following substituted radical:
-C (O) NHR " ,-C (O) OR " ,-SO
2Me ,-SO
2NHR ", cyano group, hydroxyl, alkoxyl group ,-C (S) NHR " ,-C (O) OR ", halogen or 5 to 6 yuan of assorted aromatic bases; R wherein " be selected from hydrogen atom, C
1-6Alkyl, C
1-6Cycloalkyl or C
1-6Thiazolinyl.
5. claim 2 and 3 compound, wherein R
2Be assorted aromatic base and have following substituted radical:
-C (O) NHR " ,-C (O) OR " ,-SO
2Me ,-SO
2NHR ", cyano group, hydroxyl, alkoxyl group ,-C (S) NHR " ,-C (O) OR ", halogen or 5 to 6 yuan of assorted aromatic bases; R wherein " be selected from hydrogen atom, C
1-6Alkyl, C
1-6Cycloalkyl or C
1-6Thiazolinyl.
6. claim 2,3,4 and 5 compound, wherein W is a Sauerstoffatom.
7. the compound of claim 2 has following chemical structure of general formula (II)
R wherein
1' be selected from
Wherein R ' is methyl, ethyl or CF
3Y ' is methyl, CF
3
R wherein
3' and R
4' form C together
3-5Cycloalkyl;
Wherein B is selected from cyano group, methyl, CF
3Or halogen;
Wherein A is selected from-C (O) NHCH
3,-C (O) NH
2,-C (O) OCH
3,-C (O) OCH
2CH
3, cyano group, hydroxyl, alkoxyl group ,-SO
2Me, methyl ,-SO
2NHMe or-SO
2NH
2
8. the compound of claim 3 has following chemical structure of general formula (III)
R wherein
1" be selected from
Y " be cyano group or halogen;
Wherein B is selected from cyano group, methyl, CF
3Or halogen;
Wherein A is selected from-C (O) NHCH
3,-C (O) NH
2,-C (O) OCH
3,-C (O) OCH
2CH
3, cyano group, hydroxyl, alkoxyl group ,-SO
2Me, methyl ,-SO
2NHMe or-SO
2NH
2
9. claim 7 and 8 compound, wherein W is a Sauerstoffatom.
10. the compound of claim 1 to 9 has and is selected from following chemical structural formula
11. the method for the compound of synthetic claim 1 to 10.
12. pharmaceutical composition comprises the described compound or pharmaceutically acceptable salt thereof of the claim 1-10 that treats significant quantity, compound prodrug or solution and pharmaceutically acceptable carrier or thinner.
13. be used for the treatment of the method with the active associated conditions of androgen receptor, comprise with the patient's administration of the pharmaceutical composition of claim 12 to this treatment of needs.
14. be used for the treatment of the method for responsive insensitive patient's to prostate cancer, comprise according to the patient's administration of the composition of claim 13 to this treatment of needs to hormonotherapy.
15. be used for the treatment of the method for alopecia, regeneration hair, comprise according to the patient's administration of the composition of claim 13 to this treatment of needs.
16. be used for the treatment of the method for dark sore and comedo, comprise according to the patient's administration of the composition of claim 13 to this treatment of needs.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15552309P | 2009-02-26 | 2009-02-26 | |
| US61/155,523 | 2009-02-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101817787A true CN101817787A (en) | 2010-09-01 |
| CN101817787B CN101817787B (en) | 2013-07-24 |
Family
ID=42653085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010120494 Active CN101817787B (en) | 2009-02-26 | 2010-02-24 | Androgen receptor antagonist for resisting prostate cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101817787B (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011029392A1 (en) * | 2009-09-10 | 2011-03-17 | Youzhi Tong | Androgen receptor antagonists and uses thereof |
| WO2012119559A1 (en) * | 2011-03-10 | 2012-09-13 | Suzhou Kintor Pharmaceuticals,Inc. | Androgen receptor antagonists and uses thereof |
| WO2013087004A1 (en) * | 2011-12-14 | 2013-06-20 | Chen Yuanwei | Imidazolidinedione compounds and their uses |
| WO2014036897A1 (en) * | 2012-09-04 | 2014-03-13 | 上海恒瑞医药有限公司 | Imidazoline derivatives, preparation methods thereof, and their applications in medicine |
| CN104003939A (en) * | 2014-06-06 | 2014-08-27 | 山东大学 | Diaryl substituted glycolythiourea compounds as well as preparation method and application thereof |
| CN105209045A (en) * | 2013-04-30 | 2015-12-30 | 长庚医疗财团法人林口长庚纪念医院 | Minoxidil for suppressing androgen receptor function |
| WO2018009678A1 (en) * | 2016-07-08 | 2018-01-11 | Janssen Pharmaceutica Nv | Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists |
| WO2018072300A1 (en) * | 2016-10-17 | 2018-04-26 | 成都海创药业有限公司 | Method for preparing deuterated imidazole diketone compound |
| CN110746399A (en) * | 2018-07-23 | 2020-02-04 | 上海美志医药科技有限公司 | Compound with androgen receptor degrading activity |
| CN113582977A (en) * | 2017-08-07 | 2021-11-02 | 正大天晴药业集团股份有限公司 | Diarylthiohydantoin compounds useful as androgen receptor antagonists |
| CN113861186A (en) * | 2021-09-10 | 2021-12-31 | 浙江师范大学 | Isoxazole-based substituted benzamide derivative and application of anti-prostate cancer drug |
| WO2022199577A1 (en) * | 2021-03-23 | 2022-09-29 | 苏州开拓药业股份有限公司 | Anhydrous polymorphs of androgen receptor antagonist, preparation method therefor, and use thereof |
| WO2024103494A1 (en) * | 2022-01-28 | 2024-05-23 | 南京思聚生物医药有限公司 | Locally acting androgen receptor antagonist and use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101222922A (en) * | 2005-05-13 | 2008-07-16 | 加利福尼亚大学董事会 | Diarylhydantoin compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060025589A1 (en) * | 2002-10-01 | 2006-02-02 | Jean Binet | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes |
| CN101676270A (en) * | 2004-09-09 | 2010-03-24 | 中外制药株式会社 | Novel imidazolidine derivative and use thereof |
-
2010
- 2010-02-24 CN CN 201010120494 patent/CN101817787B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101222922A (en) * | 2005-05-13 | 2008-07-16 | 加利福尼亚大学董事会 | Diarylhydantoin compounds |
Cited By (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8809550B2 (en) | 2009-09-10 | 2014-08-19 | Youzhi Tong | Androgen receptor antagonists and uses thereof |
| CN102757389A (en) * | 2009-09-10 | 2012-10-31 | 童友之 | Androgen receptor antagonists and uses thereof |
| WO2011029392A1 (en) * | 2009-09-10 | 2011-03-17 | Youzhi Tong | Androgen receptor antagonists and uses thereof |
| WO2012119559A1 (en) * | 2011-03-10 | 2012-09-13 | Suzhou Kintor Pharmaceuticals,Inc. | Androgen receptor antagonists and uses thereof |
| CN103608333B (en) * | 2011-03-10 | 2016-01-06 | 苏州开拓药业有限公司 | Androgen receptor antagonists and uses thereof |
| CN103608333A (en) * | 2011-03-10 | 2014-02-26 | 苏州开拓药业有限公司 | Androgen receptor antagonists and uses thereof |
| US9216957B2 (en) | 2011-03-10 | 2015-12-22 | Suzhou Kintor Pharmaceuticals, Inc. | Androgen receptor antagonists and uses thereof |
| JP2014510074A (en) * | 2011-03-10 | 2014-04-24 | スジョウ キンター ファーマシューティカルズ インコーポレイテッド | Androgen receptor antagonist and use thereof |
| CN104024228B (en) * | 2011-12-14 | 2015-07-08 | 成都海创药业有限公司 | Imidazolidinedione compounds and their uses |
| WO2013087004A1 (en) * | 2011-12-14 | 2013-06-20 | Chen Yuanwei | Imidazolidinedione compounds and their uses |
| CN104024228A (en) * | 2011-12-14 | 2014-09-03 | 成都海创药业有限公司 | Imidazolidinedione compounds and their uses |
| US9346764B2 (en) | 2011-12-14 | 2016-05-24 | Hinova Pharmaceuticals Inc. | Imidazolidinedione compounds and their uses |
| EP2894151A4 (en) * | 2012-09-04 | 2016-01-20 | Shanghai Hengrui Pharm Co Ltd | Imidazoline derivatives, preparation methods thereof, and their applications in medicine |
| JP2015526487A (en) * | 2012-09-04 | 2015-09-10 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | Imidazoline derivatives, their production, and their application in medicine |
| WO2014036897A1 (en) * | 2012-09-04 | 2014-03-13 | 上海恒瑞医药有限公司 | Imidazoline derivatives, preparation methods thereof, and their applications in medicine |
| US9895355B2 (en) | 2012-09-04 | 2018-02-20 | Shanghai Hengru Pharmaceutical Co., Ltd. | Methods of treating androgen receptor-mediated disorders with imidazoline derivatives |
| CN103958480A (en) * | 2012-09-04 | 2014-07-30 | 上海恒瑞医药有限公司 | Imidazoline derivatives, preparation methods thereof, and their applications in medicine |
| CN103958480B (en) * | 2012-09-04 | 2016-04-06 | 上海恒瑞医药有限公司 | Imidazolines derivative, its preparation method and in application pharmaceutically |
| KR20150047591A (en) * | 2012-09-04 | 2015-05-04 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | Imidazoline Derivatives, Preparation Methods Thereof, and Their Applications in Medicine |
| US9586947B2 (en) | 2012-09-04 | 2017-03-07 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Imidazoline derivatives, preparation methods thereof, and their applications in medicine |
| AU2013312587B2 (en) * | 2012-09-04 | 2017-03-16 | Jiangsu Hengrui Medicine Co., Ltd. | Imidazoline derivatives, preparation methods thereof, and their applications in medicine |
| KR102189940B1 (en) * | 2012-09-04 | 2020-12-14 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | Imidazoline Derivatives, Preparation Methods Thereof, and Their Applications in Medicine |
| RU2639145C2 (en) * | 2012-09-04 | 2017-12-20 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Oxothioimidazoline derivatives, methods for their production and application in medicine as androgen receptor inhibitors |
| TWI617546B (en) * | 2012-09-04 | 2018-03-11 | 上海恆瑞醫藥有限公司 | Imidazoline derivatives, preparation method and medical use thereof |
| CN105209045A (en) * | 2013-04-30 | 2015-12-30 | 长庚医疗财团法人林口长庚纪念医院 | Minoxidil for suppressing androgen receptor function |
| CN104003939A (en) * | 2014-06-06 | 2014-08-27 | 山东大学 | Diaryl substituted glycolythiourea compounds as well as preparation method and application thereof |
| CN104003939B (en) * | 2014-06-06 | 2017-07-07 | 山东大学 | Diaryl substitution thiohydantoin class compound and preparation method and application |
| WO2018009678A1 (en) * | 2016-07-08 | 2018-01-11 | Janssen Pharmaceutica Nv | Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists |
| CN110023297A (en) * | 2016-07-08 | 2019-07-16 | 詹森药业有限公司 | Substituted hydantoins and thio hydantoin derivative as androgen receptor antagonist |
| WO2018072300A1 (en) * | 2016-10-17 | 2018-04-26 | 成都海创药业有限公司 | Method for preparing deuterated imidazole diketone compound |
| CN113582977A (en) * | 2017-08-07 | 2021-11-02 | 正大天晴药业集团股份有限公司 | Diarylthiohydantoin compounds useful as androgen receptor antagonists |
| US11866433B2 (en) | 2017-08-07 | 2024-01-09 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Diarylthiohydantoin compound as androgen receptor antagonist |
| US11332465B2 (en) | 2017-08-07 | 2022-05-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Diarylthiohydantoin compound as androgen receptor antagonist |
| CN110746399A (en) * | 2018-07-23 | 2020-02-04 | 上海美志医药科技有限公司 | Compound with androgen receptor degrading activity |
| CN110746399B (en) * | 2018-07-23 | 2022-04-22 | 上海美志医药科技有限公司 | Compound with androgen receptor degrading activity |
| WO2022199577A1 (en) * | 2021-03-23 | 2022-09-29 | 苏州开拓药业股份有限公司 | Anhydrous polymorphs of androgen receptor antagonist, preparation method therefor, and use thereof |
| CN113861186B (en) * | 2021-09-10 | 2023-08-25 | 浙江师范大学 | Isoxazole-based substituted benzamide derivative and application of anti-prostate cancer drug |
| CN113861186A (en) * | 2021-09-10 | 2021-12-31 | 浙江师范大学 | Isoxazole-based substituted benzamide derivative and application of anti-prostate cancer drug |
| WO2024103494A1 (en) * | 2022-01-28 | 2024-05-23 | 南京思聚生物医药有限公司 | Locally acting androgen receptor antagonist and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101817787B (en) | 2013-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101817787B (en) | Androgen receptor antagonist for resisting prostate cancer | |
| CN102755318B (en) | Hyperproliferative disorders with diarylhydantoin compounds | |
| ES2416711T3 (en) | Siro compounds substituted as angiogenesis inhibitors | |
| CN102256983B (en) | Spiral shell oxindole compounds and its purposes as therapeutic agent | |
| CN101522685A (en) | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents | |
| BRPI0805826B1 (en) | spiro-substituted compounds, pharmaceutical composition and use | |
| CN103547567B (en) | There is the Hedgelog protein antagonist of zinc bound fraction | |
| CN102485724B (en) | Substituted thiophene base pyrazolo-pyridines and medicinal use thereof | |
| TW200901987A (en) | Triazole derivatives which are Smo antagonists | |
| CN104367575B (en) | A kind of Bouchardatine and Bouchardatine derivatives and its preparation method and application | |
| TW201002694A (en) | Quinazoline derivatives | |
| CN101627030A (en) | Compounds with partial agonist activity of ppar gamma and application thereof | |
| AU2014366436B2 (en) | Fluorophenyl pyrazol compounds | |
| JP2002541150A (en) | Substituted 1,4-dihydroindeno [1,2-c] pyrazoles as inhibitors of tyrosine kinases | |
| Chandrappa et al. | Synthesis and in vivo anticancer and antiangiogenic effects of novel thioxothiazolidin-4-one derivatives against transplantable mouse tumor | |
| CN101230045A (en) | Aromatic triazin derivatives and uses thereof | |
| CN105384738A (en) | Heterocyclic compound as protein kinase inhibitor and preparation method and application thereof | |
| CN103936650B (en) | Acid imide Phenylpiperazine derivatives and salt, preparation method and purposes | |
| US20040110768A1 (en) | Bombesin receptor antagonists | |
| Orahoske et al. | Dimeric small molecule agonists of EphA2 receptor inhibit glioblastoma cell growth | |
| CN108164520A (en) | The coupling compound and its preparation of anoxic inhibitor and antitumor drug and application | |
| CN102827160B (en) | PI3K or PI3K/m-TOR pathway inhibitor and the purposes in pharmacy thereof | |
| CN1938285B (en) | 4-anilinequinazolines with adenosine-kiase inhibitor properties | |
| CN102234270A (en) | Diarylurea derivatives and treatment application thereof | |
| CN102268014B (en) | Condensed heteroaryl derivative and its preparation method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SUZHOU KINTOR PHARMACEUTICALS INC. Free format text: FORMER OWNER: TONG YOUZHI Effective date: 20150908 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150908 Address after: Xinghu street Suzhou Industrial Park in Jiangsu province 215123 No. 218 BioBAY standing building C4-401 Patentee after: SUZHOU KINTOR PHARMACEUTICALS INC. Address before: Suzhou City, Jiangsu Province, Suzhou Industrial Park 215213 Xinghu Street No. 218 building A3 room 218 Patentee before: Tong Youzhi |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 215123 Jiangsu Suzhou Industrial Park, Suzhou No. 218 Biological Park nanmu Park research and development building C4-401 Patentee after: Suzhou pharmaceutical Limited by Share Ltd Address before: 215123 Jiangsu Suzhou Industrial Park, No. 218, bio Lake Park, C4-401 Patentee before: SUZHOU KINTOR PHARMACEUTICALS INC. |